

Anti-Obesity Drugs Market - Global Industry Size, Share, trends, Opportunity, and Forecast, Segmented By Mechanism (Peripherally Acting Drugs, Centrally Acting Drugs), By Drug Type (Prescription Drugs, OTC Drugs), By Region & Competition, 2021-2031F

<https://marketpublishers.com/r/A97E20D0B498EN.html>

Date: January 2026

Pages: 182

Price: US\$ 4,500.00 (Single User License)

ID: A97E20D0B498EN

Abstracts

The Global Anti-Obesity Drugs Market is projected to expand from USD 3.21 Billion in 2025 to USD 8.04 Billion by 2031, registering a CAGR of 16.54%. This sector comprises pharmaceutical formulations aimed at facilitating weight reduction and maintenance through mechanisms such as appetite regulation, metabolic influence, or nutrient absorption. The market is experiencing robust growth fueled by the rising prevalence of chronic weight-related disorders and the increasing acceptance of pharmacotherapy as a treatment for comorbidities like type 2 diabetes. Highlighting the urgency for effective medical interventions, updated projections from the World Obesity Federation in 2025 estimate that the global number of adults living with obesity will rise to 1.13 billion by 2030.

However, a significant obstacle to broader market expansion is the high cost of novel therapeutics coupled with inadequate insurance reimbursement policies in many regions. These financial barriers frequently restrict patient access to long-term treatment regimens and may slow the adoption of advanced weight management solutions, particularly among lower-income populations.

Market Driver

The escalating global prevalence of obesity and overweight populations serves as the primary catalyst for market expansion, creating an urgent need for therapeutic interventions to alleviate public health burdens. This deepening metabolic crisis is

driving demand for pharmaceutical solutions that address severe weight-related complications, shifting healthcare priorities toward medical management to prevent life-threatening conditions. According to the World Obesity Federation's 'World Obesity Atlas 2025', released in March 2025, overweight and obesity are responsible for approximately 1.6 million premature deaths annually from non-communicable diseases, underscoring the imperative for effective pharmacological treatments.

Concurrently, the sector has been transformed by the high clinical efficacy and commercial success of incretin-based therapies, which have established a new standard of care for regulating appetite and metabolic function. The substantial weight loss outcomes achieved by these biologics have validated pharmacotherapy for weight management, resulting in surging prescription volumes and robust revenue growth. This commercial viability is prompting competitors to accelerate the development of next-generation agonists. As noted in Novo Nordisk's 'Annual Report 2024' from February 2025, sales of its Obesity Care products rose by 57 percent to DKK 65.1 billion, while a December 2024 Fierce Pharma article reported that the company committed an additional DKK 2.9 billion to expand its quality control capabilities in Denmark.

Market Challenge

The rapid acceleration of the market is severely hindered by the high cost of novel anti-obesity medications, which often exceed thousands of dollars annually, combined with restrictive insurance policies. Health insurers and payers, wary of the financial strain associated with widespread utilization, have implemented stringent gatekeeping measures such as complex prior authorization requirements and strict body mass index thresholds. This reimbursement landscape creates a significant disconnect between clinical demand and commercial access, effectively excluding a large demographic of patients who are medically eligible but financially unable to afford out-of-pocket expenses, thereby limiting adoption primarily to affluent populations.

According to industry data cited by the Academy of Managed Care Pharmacy in 2025, only 31% of commercial plan members on average possessed coverage for anti-obesity medications, with payers citing high budget impacts as the primary barrier to broader reimbursement. This limited coverage forces the majority of potential patients to face prohibitive costs alone, directly reducing sales volume and preventing the market from reaching its full revenue potential. By restricting access to a fraction of the total addressable market, these financial barriers significantly curtail the growth trajectory of the global anti-obesity sector.

Market Trends

A dominant market force is the development of combination therapies designed to enhance tolerability and efficacy, as developers strive to surpass the clinical ceilings of mono-agonist treatments. Pharmaceutical companies are increasingly co-formulating agents with complementary mechanisms of action, such as GLP-1 analogues combined with amylin analogues, to synergistically improve metabolic outcomes and mitigate adverse events, aiming for weight loss results that rival bariatric surgery. For instance, Novo Nordisk announced in December 2024 that CagriSema, an investigational fixed-dose combination of cagrilintide and semaglutide, achieved a superior weight loss of 22.7% after 68 weeks in the REDEFINE 1 trial, significantly outperforming individual monotherapies.

Simultaneously, the sector is being reshaped by a transition toward oral small molecule formulations, which address the scalability and compliance limitations of injectable biologics. Unlike peptide-based injectables that require complex cold-chain logistics, small molecule drugs can be manufactured more cost-effectively and administered as convenient daily pills, potentially broadening patient access and adherence. This formulation evolution is rapidly advancing through clinical pipelines, offering a non-invasive alternative for long-term weight management. In November 2024, Viking Therapeutics reported that patients receiving the highest dose of its oral tablet formulation, VK2735, achieved a mean body weight reduction of up to 8.2% after just 28 days of treatment.

Key Market Players

- Alizyme PLC

- Bayer AG

- Bristol-Myers Squibb Co

- Currax Pharmaceuticals LLC

- Hoffmann-La Roche AG

- GlaxoSmithKline PLC

- Merck & Co. Inc.

%li%Norgine BV

%li%Novo Nordisk AS

%li%Pfizer Inc

Report Scope

In this report, the Global Anti-Obesity Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

%li%Anti-Obesity Drugs Market, By Mechanism

%li%%li%Peripherally Acting Drugs

%li%%li%Centrally Acting Drugs

%li%Anti-Obesity Drugs Market, By Drug Type

%li%%li%Prescription Drugs

%li%%li%OTC Drugs

%li%Anti-Obesity Drugs Market, By Region

%li%%li%North America

%li%%li%%li%United States

%li%%li%%li%Canada

%li%%li%%li%Mexico

%li%%li%Europe

%li%%li%%li%France

%li%%li%%li%United Kingdom

%li%%li%%li%Italy

%li%%li%%li%Germany

%li%%li%%li%Spain

%li%%li%Asia Pacific

%li%%li%%li%China

%li%%li%%li%India

%li%%li%%li%Japan

%li%%li%%li%Australia

%li%%li%%li%South Korea

%li%%li%South America

%li%%li%%li%Brazil

%li%%li%%li%Argentina

%li%%li%%li%Colombia

%li%%li%Middle East & Africa

%li%%li%%li%South Africa

%li%%li%%li%Saudi Arabia

%li%%li%%li%UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Anti-

Anti-Obesity Drugs Market - Global Industry Size, Share, trends, Opportunity, and Forecast, Segmented By Mecha...

Obesity Drugs Market.

Available Customizations:

Global Anti-Obesity Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

%li%Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL ANTI-OBESITY DRUGS MARKET OUTLOOK

- 5.1. Market Size & Forecast
 - 5.1.1. By Value
- 5.2. Market Share & Forecast
 - 5.2.1. By Mechanism (Peripherally Acting Drugs, Centrally Acting Drugs)
 - 5.2.2. By Drug Type (Prescription Drugs, OTC Drugs)
 - 5.2.3. By Region
 - 5.2.4. By Company (2025)

5.3. Market Map

6. NORTH AMERICA ANTI-OBESITY DRUGS MARKET OUTLOOK

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Mechanism

6.2.2. By Drug Type

6.2.3. By Country

6.3. North America: Country Analysis

6.3.1. United States Anti-Obesity Drugs Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Mechanism

6.3.1.2.2. By Drug Type

6.3.2. Canada Anti-Obesity Drugs Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Mechanism

6.3.2.2.2. By Drug Type

6.3.3. Mexico Anti-Obesity Drugs Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Mechanism

6.3.3.2.2. By Drug Type

7. EUROPE ANTI-OBESITY DRUGS MARKET OUTLOOK

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Mechanism

7.2.2. By Drug Type

7.2.3. By Country

7.3. Europe: Country Analysis

- 7.3.1. Germany Anti-Obesity Drugs Market Outlook
 - 7.3.1.1. Market Size & Forecast
 - 7.3.1.1.1. By Value
 - 7.3.1.2. Market Share & Forecast
 - 7.3.1.2.1. By Mechanism
 - 7.3.1.2.2. By Drug Type
- 7.3.2. France Anti-Obesity Drugs Market Outlook
 - 7.3.2.1. Market Size & Forecast
 - 7.3.2.1.1. By Value
 - 7.3.2.2. Market Share & Forecast
 - 7.3.2.2.1. By Mechanism
 - 7.3.2.2.2. By Drug Type
- 7.3.3. United Kingdom Anti-Obesity Drugs Market Outlook
 - 7.3.3.1. Market Size & Forecast
 - 7.3.3.1.1. By Value
 - 7.3.3.2. Market Share & Forecast
 - 7.3.3.2.1. By Mechanism
 - 7.3.3.2.2. By Drug Type
- 7.3.4. Italy Anti-Obesity Drugs Market Outlook
 - 7.3.4.1. Market Size & Forecast
 - 7.3.4.1.1. By Value
 - 7.3.4.2. Market Share & Forecast
 - 7.3.4.2.1. By Mechanism
 - 7.3.4.2.2. By Drug Type
- 7.3.5. Spain Anti-Obesity Drugs Market Outlook
 - 7.3.5.1. Market Size & Forecast
 - 7.3.5.1.1. By Value
 - 7.3.5.2. Market Share & Forecast
 - 7.3.5.2.1. By Mechanism
 - 7.3.5.2.2. By Drug Type

8. ASIA PACIFIC ANTI-OBESITY DRUGS MARKET OUTLOOK

- 8.1. Market Size & Forecast
 - 8.1.1. By Value
- 8.2. Market Share & Forecast
 - 8.2.1. By Mechanism
 - 8.2.2. By Drug Type
 - 8.2.3. By Country

- 8.3. Asia Pacific: Country Analysis
 - 8.3.1. China Anti-Obesity Drugs Market Outlook
 - 8.3.1.1. Market Size & Forecast
 - 8.3.1.1.1. By Value
 - 8.3.1.2. Market Share & Forecast
 - 8.3.1.2.1. By Mechanism
 - 8.3.1.2.2. By Drug Type
 - 8.3.2. India Anti-Obesity Drugs Market Outlook
 - 8.3.2.1. Market Size & Forecast
 - 8.3.2.1.1. By Value
 - 8.3.2.2. Market Share & Forecast
 - 8.3.2.2.1. By Mechanism
 - 8.3.2.2.2. By Drug Type
 - 8.3.3. Japan Anti-Obesity Drugs Market Outlook
 - 8.3.3.1. Market Size & Forecast
 - 8.3.3.1.1. By Value
 - 8.3.3.2. Market Share & Forecast
 - 8.3.3.2.1. By Mechanism
 - 8.3.3.2.2. By Drug Type
 - 8.3.4. South Korea Anti-Obesity Drugs Market Outlook
 - 8.3.4.1. Market Size & Forecast
 - 8.3.4.1.1. By Value
 - 8.3.4.2. Market Share & Forecast
 - 8.3.4.2.1. By Mechanism
 - 8.3.4.2.2. By Drug Type
 - 8.3.5. Australia Anti-Obesity Drugs Market Outlook
 - 8.3.5.1. Market Size & Forecast
 - 8.3.5.1.1. By Value
 - 8.3.5.2. Market Share & Forecast
 - 8.3.5.2.1. By Mechanism
 - 8.3.5.2.2. By Drug Type

9. MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET OUTLOOK

- 9.1. Market Size & Forecast
 - 9.1.1. By Value
- 9.2. Market Share & Forecast
 - 9.2.1. By Mechanism
 - 9.2.2. By Drug Type

- 9.2.3. By Country
- 9.3. Middle East & Africa: Country Analysis
 - 9.3.1. Saudi Arabia Anti-Obesity Drugs Market Outlook
 - 9.3.1.1. Market Size & Forecast
 - 9.3.1.1.1. By Value
 - 9.3.1.2. Market Share & Forecast
 - 9.3.1.2.1. By Mechanism
 - 9.3.1.2.2. By Drug Type
 - 9.3.2. UAE Anti-Obesity Drugs Market Outlook
 - 9.3.2.1. Market Size & Forecast
 - 9.3.2.1.1. By Value
 - 9.3.2.2. Market Share & Forecast
 - 9.3.2.2.1. By Mechanism
 - 9.3.2.2.2. By Drug Type
 - 9.3.3. South Africa Anti-Obesity Drugs Market Outlook
 - 9.3.3.1. Market Size & Forecast
 - 9.3.3.1.1. By Value
 - 9.3.3.2. Market Share & Forecast
 - 9.3.3.2.1. By Mechanism
 - 9.3.3.2.2. By Drug Type

10. SOUTH AMERICA ANTI-OBESITY DRUGS MARKET OUTLOOK

- 10.1. Market Size & Forecast
 - 10.1.1. By Value
- 10.2. Market Share & Forecast
 - 10.2.1. By Mechanism
 - 10.2.2. By Drug Type
 - 10.2.3. By Country
- 10.3. South America: Country Analysis
 - 10.3.1. Brazil Anti-Obesity Drugs Market Outlook
 - 10.3.1.1. Market Size & Forecast
 - 10.3.1.1.1. By Value
 - 10.3.1.2. Market Share & Forecast
 - 10.3.1.2.1. By Mechanism
 - 10.3.1.2.2. By Drug Type
 - 10.3.2. Colombia Anti-Obesity Drugs Market Outlook
 - 10.3.2.1. Market Size & Forecast
 - 10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Mechanism

10.3.2.2.2. By Drug Type

10.3.3. Argentina Anti-Obesity Drugs Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Mechanism

10.3.3.2.2. By Drug Type

11. MARKET DYNAMICS

11.1. Drivers

11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

12.1. Merger & Acquisition (If Any)

12.2. Product Launches (If Any)

12.3. Recent Developments

13. GLOBAL ANTI-OBESITY DRUGS MARKET: SWOT ANALYSIS

14. PORTER'S FIVE FORCES ANALYSIS

14.1. Competition in the Industry

14.2. Potential of New Entrants

14.3. Power of Suppliers

14.4. Power of Customers

14.5. Threat of Substitute Products

15. COMPETITIVE LANDSCAPE

15.1. Alizyme PLC

15.1.1. Business Overview

15.1.2. Products & Services

15.1.3. Recent Developments

15.1.4. Key Personnel

15.1.5. SWOT Analysis

- 15.2. Bayer AG
- 15.3. Bristol-Myers Squibb Co
- 15.4. Currax Pharmaceuticals LLC
- 15.5. Hoffmann-La Roche AG
- 15.6. GlaxoSmithKline PLC
- 15.7. Merck & Co. Inc.
- 15.8. Norgine BV
- 15.9. Novo Nordisk AS
- 15.10. Pfizer Inc

16. STRATEGIC RECOMMENDATIONS

17. ABOUT US & DISCLAIMER

I would like to order

Product name: Anti-Obesity Drugs Market - Global Industry Size, Share, trends, Opportunity, and Forecast, Segmented By Mechanism (Peripherally Acting Drugs, Centrally Acting Drugs), By Drug Type (Prescription Drugs, OTC Drugs), By Region & Competition, 2021-2031F

Product link: <https://marketpublishers.com/r/A97E20D0B498EN.html>

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A97E20D0B498EN.html>